This paper delves into the challenges and opportunities surrounding the production and distribution of essential medicines for asthma and COPD in LMICs. It emphasizes the importance of local pharmaceutical production in ensuring access to quality medicines, especially in low and middle-income countries. The paper highlights that while Africa bears a significant burden of global diseases, it has limited capacity to produce essential medicines, leading to a heavy reliance on imports. This dependency makes the continent vulnerable to global supply chain disruptions, price fluctuations, and counterfeit products.
To address these challenges, the document underscores the need for strengthening regulatory frameworks, enhancing local production capacities, and fostering regional collaboration. It suggests that investments in local pharmaceutical industries can lead to job creation, technology transfer, and improved public health outcomes. The paper also touches upon the role of international partnerships and collaborations in building a resilient and sustainable pharmaceutical sector in LMICs.
In conclusion, the document advocates for a strategic approach to boost local pharmaceutical production in LMICs, emphasizing the need for quality assurance, capacity building, and regional cooperation to ensure that essential medicines are accessible and affordable to all.
You can submit a specific query to QUAMED experts by clicking on the button below. We will send relevant answers directly to your mailbox.
Submit Query
The information provided on this Web site is not official U.S. Government information and does not represent the views or positions of the U.S. Agency for International Development or the U.S. Government.
ISO 9001:2015 - FS766975
© 2024 - QUAMED
Content of this site is licensed under a Creative Commons License- BY Attribution